Codexis (CDXS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Voting matters and shareholder proposals
Election of three Class I directors for a three-year term expiring at the 2029 Annual Meeting, with nominees Stephen G. Dilly, Raymond De Vré, and Rahul Singhvi recommended by the board.
Ratification of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Advisory vote to approve the compensation of named executive officers.
Proxies authorized to vote on other business that may arise at the meeting or any adjournment.
Board of directors and corporate governance
Board recommends all three director nominees for election to serve until the 2029 Annual Meeting.
Audit committee and external auditor matters
Audit Committee selected KPMG LLP as the independent registered public accounting firm for the upcoming fiscal year.
Latest events from Codexis
- Q1 2026 revenue doubled, net loss narrowed, and cash reserves support ongoing growth.CDXS
Q1 20267 May 2026 - Annual meeting to vote on directors, auditor, and executive pay, with board support for all proposals.CDXS
Proxy filing28 Apr 2026 - 2025 revenue up 19% to $70.4M, Q4 profitable, 2026 outlook strong with $72–76M guidance.CDXS
Q4 202511 Mar 2026 - ECO Synthesis platform drives RNA medicine manufacturing growth, targeting a $2B market by 2030.CDXS
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Q2 revenue met expectations; guidance and double-digit growth outlook reaffirmed.CDXS
Q2 20242 Feb 2026 - Enzymatic siRNA synthesis advances, driving new partnerships and strong revenue growth outlook.CDXS
Jefferies Global Healthcare Conference1 Feb 2026 - ECO Synthesis enables scalable, cost-effective siRNA production, driving growth and industry adoption.CDXS
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026 - Q3 2024 revenue up 38%, margin at 61%, net loss narrowed, cash runway extended to 2027.CDXS
Q3 202417 Jan 2026 - First end-to-end enzymatic siRNA synthesis achieved, driving demand for scalable RNAi manufacturing.CDXS
Status Update13 Jan 2026